Recruiting Endometrial Cancer Studies in Duarte
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemot...
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembroliz...
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (pac...
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer....
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) o...
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurren...
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
This is a 2 stage multi-center study designed to evaluate the efficacy of the combination of alpelisib and fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by e...
About Endometrial Cancer Clinical Trials in Duarte
Endometrial cancer begins in the lining of the uterus and is the most common gynecologic cancer. It is often detected early due to abnormal bleeding symptoms. Treatment typically involves surgery, with radiation, chemotherapy, or hormone therapy for advanced cases.
There are currently 7 endometrial cancer clinical trials recruiting participants in Duarte, CA. These studies are seeking a combined 2,372 participants. Research is being sponsored by Gilead Sciences, AstraZeneca, National Cancer Institute (NCI) and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Endometrial Cancer Clinical Trials in Duarte — FAQ
Are there endometrial cancer clinical trials in Duarte?
Yes, there are 7 endometrial cancer clinical trials currently recruiting in Duarte, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Duarte?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you about next steps.
Are clinical trials in Duarte free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Duarte studies also compensate for your time and travel.
What endometrial cancer treatments are being tested?
The 7 active trials in Duarte are testing new therapies including novel drugs, biologics, and treatment approaches for endometrial cancer.
Data updated March 2, 2026 from ClinicalTrials.gov